This observational study is looking at how immune cells called monocytes (a type of white blood cell) behave in people who have both Type 1 Diabetes (T1D) and Chronic Kidney Disease (CKD). Researchers want to see if the amount of time your blood sugar is in a healthy range (Time in Range, or TIR) affects how these monocytes react to high blood sugar. They will also explore if a type of medication called a GLP-1 agonist, when tested in the lab, can reduce this monocyte reaction. The study is comparing monocytes from people with T1D and CKD to those with T1D but without CKD. You might be eligible if you are 18-65 years old, have T1D and CKD (with an eGFR between 60-90 ml/min/1.73 m2 and albumin in your urine), and use insulin and a continuous glucose monitor (CGM). The study is looking for 60 participants. Success would mean finding out how monocytes react to different blood sugar levels and if GLP-1 agonists can help. The current recruitment status is unclear.

Study design

This is an observational study with a planned enrollment of 60 participants. It is a cross-sectional study, meaning data is collected at a single point in time.

What's involved

You would have an initial phone screen, followed by a formal screening visit to check if you are eligible. If eligible, you would return for one study visit within 4 weeks for a blood draw.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.